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ABSTRACT
The incidence and mortality rates from endometrial cancer are increasing. There 
have been no new drugs approved for the treatment of endometrial cancer in decades. 
The National Cancer Institute, Gynecologic Cancer Steering Committee identified 
the integration of molecular and/or histologic stratification into endometrial cancer 
management as a top strategic priority. Based on this, they convened a group of 
experts to review the molecular data in this disease. Here we report on the actionable 
opportunities and therapeutic directions identified for incorporation into future clinical 
trials.
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INTRODUCTION
Endometrial Cancer (EC) is the fourth most 
common cancer affecting women. Over the last decade, 
the incidence of EC has been increasing globally. If 
current trends continue, in the United States the incidence 
of EC will double by 2030 [1]. Furthermore, the number 
of women dying from EC has also been increasing 
disproportionally to the rise in incidence, with rates 
exceeding those seen for most other solid tumors [2]. 
There are few therapeutic options for women diagnosed 
with recurrent or metastatic EC, and median overall 
survival (OS) is short. No new agents have been approved 
for the treatment of EC in the past two decades [3]. 
New therapeutic approaches are required to meet this 
significant unmet need. In many other cancers, a detailed 
understanding of underlying tumor biology has yielded 
remarkable advances in therapeutic interventions, most 
often when agents are administered in target-selected 
populations. Not only does this potentially enrich for 
benefit for patients and clarity in interpretation, but it 
would also allow differentiation between presence of 
mutation and functionally actionable events. Applying this 
approach to EC is critical if we are to improve outcomes 
for women diagnosed with this disease.
The US National Cancer Institute (NCI) 
Gynecologic Cancer Steering Committee (GCSC) 
identified the integration of molecular and/or histologic 
stratification into EC management as a top strategic 
priority in clinical trial planning. Based on this input the 
NCI convened a Uterine Cancer Clinical Trials Planning 
Meeting (UCTPM) in January 2016. The focus of the 
UCTPM was to review and apply emerging molecular 
knowledge of EC to yield clinical trial concepts for 
testing actionable events in molecularly defined recurrent 
EC patient populations. Prior to the January meeting, a 
group of experts were assembled to consider the published 
literature focusing particularly on reports related to human 
specimens, with the goal of identifying evidence to 
support therapeutic approaches for near-term clinical trial 
application. Reports were generated on a number of key 
areas including DNA repair, hormone-related pathways, 
ERBB2/HER2, PI3K/AKT/mTOR signaling, the 
ubiquitin-ligase complex, the WNT pathway, the immune 
system, and obesity-driven targets. We summarize the key 
findings from these individual reports below and indicate 
reasonable candidate approaches for near-term clinical 
trial planning.
MOLECULAR CLASSIFICATION OF 
ENDOMETRIAL CANCERS
Prognostic models for risk of metastatic disease 
or recurrence have been found to be of limited value in 
EC [4]. EC grade and histotype are major components 
of the models and are historically associated with poor 
reproducibility, with inter-observer disagreement in 
one third of high grade ECs [5, 6]. Thus, unlike other 
gynecologic cancers, it has become apparent that 
histologic subtype alone may not be the most effective 
approach to stratify and guide the treatment of EC. The 
traditional view of EC classification lacks the accuracy 
needed to sufficiently discriminate biologic variants to 
guide treatment.
The Cancer Genome Atlas (TCGA) project in 
2013 examined nearly 500 samples of newly diagnosed 
endometrioid and serous ECs [7]. Detailed analysis 
allowed organization into four molecular subgroups based 
upon shared genomic features that correlated with clinical 
outcome. The four subgroups were: POLE-ultramutated 
(POLE), microsatellite instability-hypermutated (MSI), 
copy number low-microsatellite stable (CNL), and copy 
number high-serous-like (CNH). This classification is 
driving a paradigm shift in how EC is viewed, opening 
new possibilities for risk stratification, and identifying 
potential, actionable, subgroup-specific therapeutic 
targets.
The POLE subgroup is characterized by a very high 
mutation burden driven by POLE exonuclease-domain 
mutations. This subgroup has a very favorable clinical 
outcome despite including tumors of varied grade and 
histology. The MSI subgroup is characterized by MSI 
and has a high mutation burden with frequent MLH1 
promoter methylation. The clinical significance of MSI 
in EC is uncertain, but it is frequently associated with an 
active immune cell infiltrate [8]. The CNL subgroup has 
low histological grade and frequent CTNNB1 mutations 
without MSI or TP53 mutations. PTEN mutations are 
very common in the MSI and CNL subgroups and 
infrequent in the CNH subgroup [7]. The CNH subgroup 
is defined by the presence of somatic TP53 mutations, 
and included nearly all uterine serous carcinomas and 
~25% of high-grade endometrioid tumors. A number of 
groups are developing clinically applicable classifiers to 
identify these molecular subgroups, which are undergoing 
prospective validation [9, 10] (Figure 1).
Achieving the goal to minimize therapy where it is 
not needed, and to tailor treatment to the cancer and patient 
is most likely to be achieved by incorporating molecular 
subgroup stratification into current classification schemas. 
This will allow us to prospectively test the value of such 
molecular subgroup stratification on treatment selection 
and outcome. Consideration should be given to the impact 
of the molecular subgroups on outcome when analyzing 
and interpreting existing and upcoming data from clinical 
trials including mixed populations of EC patients.
Serous ECs are characterized by genomic instability, 
high rates of somatic mutations in the TP53, PPP2R1A, 
FBXW7, PIK3CA, PIK3R1, PTEN, SPOP, CHD4, and 
TAF1 genes [7, 11–16] frequent amplification and/or 
overexpression of the ERBB2/HER2 receptor tyrosine 
kinase [17, 18], and dysregulated expression of cyclin 
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E, c-MYC, p16, E-cadherin, claudin-3, claudin-4, 
L1CAM and EpCAM [19]. Mutations in chromatin 
remodeling genes have also been reported [14, 16]. The 
TCGA classified 98% of serous ECs, 5% of low-grade 
endometrioid ECs (EECs), 19% of high grade EECs, and 
75% of mixed histology ECs into a single molecular group 
referred to as “serous-like EC” because of their overall 
molecular resemblance to uterine serous carcinoma [7].
POTENTIAL TARGETS AND 
THERAPEUTIC OPPORTUNITIES
DNA repair
Classic cytotoxic agents cause DNA damage, 
and many newer agents lead to cell death through 
the inhibition of DNA repair. A major mechanism for 
augmentation of injury is to exploit DNA repair and cell 
cycle defects. Agents that prevent DNA repair or inhibit 
the cell cycle checkpoint cause rapid throughput in G1/S 
and G2/M. Such cell cycle progression results in cellular 
accumulation of DNA damage and subsequent apoptosis 
or mitotic catastrophic cell death.
The TCGA analysis identified genomic events that 
suggest EC, known to be susceptible to DNA damaging 
agents, may be affected by targeting DNA repair [7, 
20]. These include: the high mutational profiles, TP53 
mutation, PTEN loss, and ARID1A mutations. PTEN loss 
of function in EC, frequent in all TCGA subgroups except 
CNH, may confer a homologous recombination (HR) 
deficiency phenotype, similar to that seen in deleterious 
germline BRCA1 and BRCA2 mutations [21]. In vitro 
sensitivity to polyADP-ribose polymerase inhibitors 
(PARPi) has been demonstrated in PTEN-null cell lines 
[21]. This remains controversial, with others finding no 
association with PTEN loss and response to PARPi [22]. 
Cell line data from colorectal and endometrial cancers 
suggest MSI tumors may harbor mutations in other genes 
involved in HR repair of double strand DNA breaks, e.g., 
MRE11A and RAD50 [23–25]. ARID1A mutations are 
present in ~40% of MSI and CNL endometrioid tumors. 
ARID1A is recruited to DNA breakage sites through 
interaction with ATR and is required for normal G2/M 
checkpoint inhibition [26]. ARID1A functional loss 
impairs ATR activation by DNA double-strand breaks and 
is associated with sensitization to PARPi, and also may 
sensitize to platinum chemotherapy and radiation. The use 
of agents targeting DNA repair may also be of interest in 
the MSI subgroup of EC.
The number of classes of agents targeting inhibition 
of DNA repair continues to expand beyond the PARPi. 
Promising targets include ATM and ATR, and WEE1 
and CHEK1 G2 checkpoint kinases. Preclinical data 
suggest that combining ATR inhibitors with platinum 
may provide an effective treatment of platinum resistant 
EC [27]. WEE1 and CHEK1 are involved in the normal 
G2/M transition. Data to date suggest that cancers with a 
dependence on G2/M DNA repair may be susceptible to 
inhibition with DNA repair inhibitors. Combining agents 
targeting DNA repair is an attractive potential therapeutic 
Figure 1: Suggested potential schema for molecular classification of endometrial cancer using sequencing and IHC 
results to segregate patients into the molecular subtypes previously defined by the TCGA.
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strategy [20, 28–30] (Figure 2). Combinations with 
other targeted agents, to create context-specific synthetic 
lethality are also promising.
Estrogen (ER) and progesterone (PR) receptor 
related pathways
Endocrine therapy has been investigated for the 
treatment of EC for over two decades. The 2010 Cochrane 
Review concluded that there was “no improvement in 
survival for women receiving endocrine therapy for 
advanced EC”. This conclusion, however, was limited by 
the lack of the large-scale randomized trials that would 
be necessary to show benefit [31]. There remains a strong 
rationale for endocrine therapy in EC, particularly in low 
grade cancers, which requires further investigation in 
light of our increased understanding of the EC molecular 
landscape.
Single agent progestins have yielded overall 
response rates of 20-25% [32], with some studies 
suggesting that ERα or PR expressing cancers are more 
likely to respond, although the overall data are inconsistent 
[32–34]. This serves to highlight the importance of 
standardizing tissue choice and handling, and analysis 
of receptor status when investigating endocrine therapy 
in EC. Many ECs have low levels or gradual loss of PR 
such that durable responses to therapy are rarely achieved. 
Agents targeting estrogen dependent pathways have also 
shown modest efficacy [35–38].
Explorations of strategies to increase hormone 
receptor expression are of interest. A 2004 GOG phase II 
study investigated tamoxifen alternating with megestrol 
acetate in order to increase PR expression in women 
with advanced and metastatic EC. A response rate of 
27% was observed with a median OS of 14 months [39]. 
Recently in vitro studies suggest inducing changes in 
the epigenome could be a potential therapeutic strategy 
to increase hormone receptor expression. Differential 
methylation of multiple genes has been extensively 
reported in EC [40–43]. Aberrant DNA hypermethylation 
Figure 2: Augmenting DNA damage and repair: potential therapeutic directions (adapted from Ivy et al., 2016) [20].
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appears to be more frequent in lower grade endometrioid 
EC, with DNA hypomethylation a feature of serous-
like EC [7]. Silencing of both ERα and PR by aberrant 
promoter methylation is reported in cell lines and patient 
samples with hypermethylation of the ERα-promoter C 
reported in over 90% and PR-promoter B in 70% of cases 
[44]. Treatment with a DNA methyltransferase inhibitor 
resulted in increased PR expression in several cell line 
studies. Histone modification also appears to influence 
PR expression. PR mRNA silencing has been shown to 
be reversed and functional PR expression restored with 
the use of epigenetic modulators in hormone-unresponsive 
EC cell lines [45]. HDAC inhibitors and demethylating 
agents are available for study and should be considered in 
combination with endocrine therapy.
Combining hormonal therapy with targeted 
therapies in rationally designed clinical trials is also 
an attractive therapeutic direction. Targeting the 
phosphoinosital-3 kinase (PI3K)/AKT/mammalian target 
of rapamycin (mTOR) pathway has been proposed as a 
mechanism for overcoming endocrine therapy resistance. 
Data predominantly in breast cancer suggest that cross 
regulation between the ER and PI3K/AKT/mTOR 
pathways makes targeting both pathways an attractive 
option [46]. Initial studies in EC with the rapalog class 
of mTOR inhibitors resulted in a clinical benefit rate 
(CBR) of 40% with an objective response rate of 32% 
for the combination of letrozole and everolimus [47]. 
The strongest indicator of lack of benefit from that 
treatment was serous histology. There was a statistically 
marginal benefit for the small subset of patients with 
catenin-beta 1 CTNNB1 mutations. However, given the 
intra-pathway feedback loops, inter-pathway crosstalk 
and the incomplete blockade of the mTOR complex by 
the rapalogs, the limited response and duration of this 
combination suggests there may be further scope to 
optimize this strategy.
Another direction to increase hormonal therapy 
efficacy would be to focus on its multiple escape pathways. 
Provisional data from a study combining metformin, 
letrozole and everolimus demonstrated a CBR of 60% 
[48]. However, the combination of temsirolimus with 
alternating megestrol acetate and daily tamoxifen did not 
add benefit relative to hormonal therapy alone, and was 
associated with high rates of venous thromboembolism 
[49]. Exploratory biomarker work in this study and the 
everolimus/letrozole trial suggests that tumors harboring 
CTNNB1 mutations may be more likely to respond, 
although responses were also seen in tumors with wild 
type CTNNB1 [50].
Extrapolating from the experience in breast 
cancer, other options include combinations of endocrine 
therapy with cyclin dependent kinase inhibitors [51]. 
Elevated CDK4 expression has been reported in 34-
77% of endometrioid ECs [52, 53]. The combination of 
palbociclib and letrozole is currently under investigation 
(NCT 02730429). Correlative studies incorporated into 
clinical trials will be invaluable in optimizing endocrine 
therapy combination strategies and patient selection.
PI3K/AKT/mTOR pathway
The PIK3CA-PIK3R1-PTEN axis is somatically 
mutated in at least 40% of serous ECs and over 70% of 
endometrioid EC [7, 15, 54]. A large fraction of PIK3CA 
mutations are located in exons 1-8, in addition to exons 
9 and 20 [11]. These mutations were found across all 
TCGA subgroups. Clinical trials of the rapalog class 
of mTOR inhibitors, temsirolimus, everolimus and 
ridaforolimus, have been completed in EC [49, 55–57]. 
Response rates have been modest with some patients 
experiencing prolonged stable disease. To date Correlative 
analyses of archival biospecimens have failed to identify 
a predictive biomarker [58, 59]. It is likely that a single or 
several biomarkers may be insufficient to predict clinical 
benefit due to complexity of this pathway and its many 
interactions in tumors, and the incomplete blockade of 
the pathway provided by these agents. There are multiple 
completed or ongoing single agent phase II clinical trials 
examining non-rapalog PI3K/mTOR agents in EC. A 
phase II trial (NCT01455493) of the PI3K/mTORC1/2 
inhibitor, MK2206, in patients with advanced EC enrolled 
56 patients, 3 patients had a confirmed clinical response 
and all 3 had one or more molecular abnormalities in 
PIK3CA, PTEN, or AKT [60]. A number of preclinical 
studies have shown that HER2-amplified serous cell lines 
were more sensitive to growth inhibition by mTORC1/2 
inhibitors than HER2 non-amplified serous EC cell lines, a 
potential future direction. Targeting the PI3K/AKT/mTOR 
pathway alone or in combination remains an active area 
of research in EC. A new study has opened to examine 
the role of the PI3K inhibitor, copanlisib, in patients with 
PI3KCA hot spot mutations in their EC. (NRG GY008/
NCT02728258).
Immune related pathways
Solid tumors frequently harbor an immune infiltrate 
that bi-directionally regulates cancer cell growth and 
metastatic potential, and in many cancers, has been 
demonstrated to have prognostic impact. Therapeutic 
immune modulation of this infiltrate could therefore be 
employed to optimize patient-tailored treatment and 
potentially outcome. The presence of tumor infiltrating 
lymphocytes (TiLs) and high ratios of CD8+TiLs to 
FoxP3+ T regulatory cells are associated in EC with a 
favorable prognosis [61], as are the presence of CD3+ 
T cells [61, 62] and CD45RO memory T cells [61]. On 
the other hand, the presence of CD163+ tumor-associated 
macrophages [63], CD4+CD25+ and CD4+FoxP3+ 
regulatory T cells, and high ratios of regulatory T cells 
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to CD8+ cells were associated with a worse prognosis 
[64, 65]. This provides the impetus for using and 
understanding the role of agents that will enhance the 
presence of anti-tumor T-lymphocytes in the tumor tissue 
and microenvironment, and reduce the effect of local 
inhibitory factors, such as regulatory T cells.
The POLE subtype identified by TCGA has a 
good prognosis and displays enhanced cytotoxic T 
cell responses and high neoantigen load. Increased 
cytotoxic T cell responses are also seen in the TCGA 
identified MSI subgroup [8, 66]. MSI-associated EC are 
known to have a propensity for lower uterine segment 
involvement, intratumoral heterogeneity, and dense 
peritumoral lymphocytic infiltration [67]. Since both 
POLE and MSI subtypes demonstrate overexpression of 
PD1 and PDL1, these patients have been proposed to be 
excellent candidates for PD1-targeted therapies [68]. A 
recent meeting presentation reported 7 of 10 (70%) MSI 
EC responded to pembrolizumab within the KEYNOTE 
158 study. There are multiple ongoing and planned trials 
of PD1-targeted therapy as single agents, with other 
immune modifying drugs, or with classic cytotoxic agents 
in microsatellite stable and unstable tumors. Further 
characterization of the immunological landscape of the 
copy-number low, copy-number high, and TP53 mutant 
high-risk ECs may result in additional patient-tailored 
immunological therapies.
Antigen-specific immunotherapy aims at activating 
the adaptive immune system towards a specific tumor-
antigen. These vaccines may be the strategy of choice for 
patients with low anti-tumor immune responses, as these 
patients do not meet the criteria for checkpoint inhibition 
or adoptive T cell therapy. Important criteria for target 
tumor-associated antigens are no or low expression in 
healthy tissues and overexpression in EC. Examples of 
tumor-associated antigens that may be targeted using 
this strategy are survivin and Wilms’ tumor gene 1 
(WT1). In an analysis of the immunogenicity of survivin, 
spontaneous T cell responses were seen in 10/39 EC 
patients [69]. Vaccination with autologous dendritic cells 
electroporated with WT1 mRNA generated a response in 
3 out of 4 HLA-A2 patients, and a WT1-specific T cell 
response was seen in 2 of these patients [70]. It has been 
suggested that a combination of antigen-specific vaccines 
and chemotherapy may be synergistic as chemotherapy 
may lead to increased antigen uptake by antigen presenting 
cells and direct activation of dendritic cells.
Obesity-related pathways
Obesity, diabetes and insulin resistance are 
associated with increased risk of developing EC and 
worse prognosis for incident EC [71–75]. Epidemiological 
evidence suggests that use of metformin, as first line 
treatment for type 2 diabetes, lowers cancer risk and 
reduces cancer deaths among diabetic patients, including 
women with EC [75–79]. Although the hypotheses are 
controversial, metformin may exert anti-tumorigenic 
activity through indirect effects on the metabolic milieu 
via cation-selective transporters and direct effects on the 
tumor through inhibition of mitochondrial complex 1 
and subsequent AMPK activation and mTOR pathway 
inhibition [80, 81].
Several pre-operative window studies of metformin 
in EC are reported [82–85]. Each reported a statistically 
significant decrease in expression of Ki-67, a marker of 
cell proliferation, and reduction in downstream markers 
of the MAPK and mTOR pathways. Metformin treatment 
also decreased circulating plasma factors, including 
insulin, glucose, insulin-like growth factor-1 (IGF-1), 
leptin and insulin-like growth factor binding protein-7 
(IGFBP7). Discrepant results have been reported on the 
effect of metformin on phosphorylated-AMPK [82].
There are currently many studies of metformin 
for endometrial hyperplasia or cancer (Table 1). These 
include chemoprevention in the obese patient, treatment 
of endometrial hyperplasia, and combination therapy with 
other targeted agents. An ongoing randomized, placebo-
controlled phase II/III trial is designed to assess efficacy 
of the addition of metformin to paclitaxel and carboplatin 
in women with advanced and recurrent EC (GOG-0286B; 
NCT02065687). Secondary endpoints are to estimate 
differences in obesity-related parameters, cation transport, 
and demographics.
ERBB2/ HER2
ERBB2/HER2 is a receptor tyrosine kinase that 
mediates signaling via the PI3K and mitogen activated 
protein kinase (MAPK) pathways. It is amplified in 
21%-47% of serous ECs, found in the TCGA CNH 
subgroup, and in 3%-21% of endometrioid ECs [86, 87]. 
Trastuzumab is a humanized monoclonal antibody that 
targets HER2. Although clinical responses to trastuzumab 
in HER2+ serous and endometrioid EC cancer patients 
have been noted in case reports [88, 89], a phase II trial 
(GOG181B) evaluating the activity of trastuzumab for 
HER2+ recurrent or advanced-stage EC observed no 
objective responses [89, 90]. Studies in tumor tissues and 
serum from EC patients raise the possibility that ECs may 
be intrinsically resistant to trastuzumab because they have 
relatively high levels of the p95 variant of HER2, which 
lacks the extracellular domain targeted by trastuzumab 
[91, 92], or because of the frequent somatic activation 
of the downstream PI3K pathway [93]. It has therefore 
been hypothesized that small molecule inhibitors that bind 
the intracellular domain of both HER2 and p95, such as 
lapatinib, might be more effective than trastuzumab in 
EC. A phase II trial of lapatinib in unselected patients 
with recurrent or persistent EC observed limited clinical 
activity [94]. Potential explanations for the limited 
activity included recruitment of unselected patients, 
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Table 1: Table Obesity pathway vs. Table Metformin studies





Metformin for the Treatment 
of Endometrial Hyperplasia
Open label, safety/efficacy 
trial






Metformin with the 
Levonorgestrel- Releasing 
Intrauterine Device for 
the Treatment of Complex 
Atypical Hyperplasia (CAH) 
and Endometrial Cancer 
(EC) in Non-Surgical 
Patients
Open label, safety/efficacy 
trial
Complex atypical 
hyperplasia and endometrial 
cancer
M.D. Anderson Cancer 
Center
NCT01697566
An Endometrial Cancer 
Chemoprevention Study 
of Metformin Versus No 
Treatment in Women 
with a Body Mass Index 
(BMI) >/= 35 kg/m2 and 
Hyperinsulinemia
Randomized, double blind, 
phase III efficacy trial
Endometrial Cancer
M.D. Anderson Cancer 
Center
NCT01797523
A Phase II, Single-
Arm Study of RAD001 
(Everolimus), Letrozole, 
and Metformin in Patients 
with Advanced or Recurrent 
Endometrial Carcinoma






A Randomized Phase II/




Placebo as Initial Therapy 
for Measurable Stage III or 
IVA, Stage IVB, or Recurrent 
Endometrial Cancer
Randomized, double blinded, 
placebo controlled, phase II/
III trial
Endometrial Cancer
Queensland Centre for 
Gynaecological Cancer
NCT01686126
Improving the Treatment for 
Women with Early Stage 
Cancer of the Uterus
Randomized, open label, 
efficacy, phase II, Mirena 
IUD versus, Mirena 
IUD + Metformin versus 
Mirena IUD + Weight Loss 
Intervention




Megestrol Acetate Plus 
Metformin to Megestrol 
Acetate in Patients with 
Endometrial Atypical 
Hyperplasia or Early 
Stage Endometrial 
Adenocarcinoma
Randomized, open label, 
efficacy, phase II
Endometrial hyperplasia with 
atypia, Endometrial Cancer
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and/or intrinsic lapatinib-resistance due to activation of 
the PI3K pathway. Afatinib, a pan-ERBB inhibitor, is 
currently under investigation in a phase II clinical trial in 
patients with persistent or recurrent HER2+ uterine serous 
carcinoma (NCT02491099).
TCGA has shown that amplification of HER2 and 
somatic mutations of PIK3CA, the p110 kinase subunit 
of PI3K, often co-occur in serous/serous-like EC [7]. 
Whether these events occur within the same or distinct 
subpopulations of a given tumor remains to be determined 
and may have clinical implications, as noted for breast 
cancer [95]. It would seem prudent that future clinical 
trial design of HER2 targeted therapies in EC should 
include a comprehensive molecular assessment of the 
PI3K pathway, including PIK3CA (all exons), PTEN, and 
PIK3R1, the gene encoding the p85α regulatory subunit 
of PI3K. Combination therapy of pan-ERBB inhibitors 
with PI3K inhibitors has been shown to be synergistic 
in preclinical models of serous cancer [96]. Importantly, 
dual inhibition initiated after tumor progression with 
single agent treatment was still effective in inducing 
tumor regression in tumor bearing mice. Thus, dual HER2/
PIK3CA blockade may represent a novel therapeutic 
option for EC patients harboring tumors with HER2 gene 
amplification and mutated PIK3CA.
WNT pathway
WNT signaling functions predominantly through 
both CTNNB1-dependent, and independent pathways, 
often termed canonical and non-canonical WNT signaling, 
respectively [97–99]. The WNT pathway is typically 
activated by one of the WNT family members binding 
to the frizzled (FZD) receptor to activate the disheveled 
(DVL) protein (Figure 3). This pathway is deregulated in 
many human tumors. Under normal conditions, CTNNB1 
is phosphorylated by WNT pathway members and targeted 
for proteasomal degradation through ubiquitination, 
leading to active repression of CTNNB1 target genes. 
When the pathway is disrupted, such as somatic mutations 
in pathway members or CTNNB1, CTNNB1 is not targeted 
for degradation, avoids phosphorylation, and accumulates 
in the cytoplasm, ultimately entering the nucleus and 
leading to CTNNB1-mediated transcription. Secreted 
WNT antagonists include members of the Dickkopf (Dkk) 
family that prevent Wnt signaling through the low-density 
lipoprotein receptor-related protein (LRP). Dkk3 has been 
shown to be downregulated in EC and correlated with 
advanced stage and high-risk clinicopathologic factors. 
Forced Dkk3 expression in vitro reduced proliferation, 
anchorage-independent growth, and invasion [100].
WNT signaling in EC predominantly involves the 
CTNNB1-dependent, or canonical, signaling pathway. 
CTNNB1 mutations occur in 52% of the CNL EC subgroup 
identified in the TCGA [7]. Alterations are uncommon 
among serous tumors and are present at low frequency 
in MSI+ tumors. Several studies have suggested that 
CTNNB1 mutations are associated with a worse prognosis 
in early-stage low grade EC [101]. The accumulation 
of nuclear CTNNB1 has been demonstrated to be more 
common in high-grade EC and associated with loss of 
CDH1, suggesting more aggressive behavior [102]. There 
are few WNT pathway targeted agents available currently 
[103]; such agents would be of interest to explore in EC.
Ubiquitin-ligase complexes
The proper regulation of cellular protein levels by 
the ubiquitin proteosome system is an important facet 
of cell biology. Dysregulation of ubiquitin mediated 
proteosomal degradation of cellular proteins is often 
observed in human cancers [104, 105]. Recent whole 
exome sequencing studies in EC have uncovered frequent 
somatic alterations in the FBXW7 and SPOP genes, 
which encode ubiquitin ligase adaptor proteins and are 
more commonly seen in the CNH TCGA subgroup. This 
pathway is thus a novel direction for consideration. The 
SKP1-CUL1-FBXW7 (SCFFBXW7) complex is an E3 
ubiquitin ligase complex that regulates the degradation 
of a large number of protein substrates, many of which 
are transcriptional regulators [106]. Several proteins that 
are regulated by the SCFFBXW7 complex, such as cyclin E, 
cMYC, mTOR, and MCL1 promote oncogenesis in solid 
tumors. FBXW7 is a haplo-insufficient tumor suppressor 
[107], and is somatically mutated and/or deleted across a 
wide range of human cancers, with EC and T cell acute 
lymphocytic leukemias most frequently mutated [7, 14, 
106, 108, 109]. Comprehensive sequencing studies in EC 
have shown that FBXW7 mutations are more abundant in 
serous (15%-29%) [7, 14, 16, 109] and serous-like (21%) 
[7] cancers, than in either clear cell (7%-13%) [14, 110] 
or endometrioid (10%-27%) ECs [7, 14]. The presence 
of FBXW7 mutations in concurrent cases of serous 
EC and serous endometrial intraepithelial carcinoma 
suggests these are early genetic events for this subtype 
[109]. In addition, FBXW7 is also mutated in 20% of 
undifferentiated uterine carcinomas and in 23% of uterine 
carcinosarcomas [111–113].
The SPOP-CUL3-RBX1 ubiquitin ligase complex 
also regulates protein turnover via ubiquitin-mediated 
proteasomal degradation. Thus far, the repertoire of 
proteins that are regulated by the SPOP-CUL3-RBX1 
complex appears to be largely distinct from those that are 
regulated by the SCFFBXW7 complex. Although somatic 
mutations in SPOP are rare in most human cancers, 
they occur at higher rates in EC [7, 14, 16], and prostate 
cancer [114]. SPOP mutations have been documented 
in 7%-8% of serous ECs [7, 14, 16], 5% of serous-like 
ECs [7], 0-9% of endometrioid ECs [7, 16], and 8% of 
clear cell ECs [14]. The majority of SPOP mutations in 
EC and in prostate cancer localize to the MATH domain, 
which binds proteins that are targeted for ubiquitination 
and proteasomal degradation. The MATH domain of 
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SPOP functions in an analogous manner to the WD repeats 
of FBXW7, leading to the speculation that missense 
mutations in the MATH domain are likely to be dominant-
negative or loss-of-function mutants that disrupt the 
binding of SPOP to one or more of its protein substrates. 
Functional studies of the SPOP mutations that have been 
found in EC are at a very early stage, but thus far indicate 
that a subset of SPOP mutants have an impaired ability to 
regulate ERα [115]. Recent work by Barberi et al., 2015 
indicates that SPOP mutations in prostate cancer lead to 
defects in HR and confer sensitivity to PARP inhibition 
[114]. Whether this phenomenon also holds true for EC, 
remains to be elucidated.
Chromatin-remodeling
Mutated chromatin-remodeling genes have been 
reported in primary serous EC. Whole-exome sequencing 
analysis of a small number of primary serous endometrial 
tumors (n=13), followed by targeted gene sequencing in a 
larger cohort of serous ECs, identified frequent somatic 
mutations in CHD4 (17%), which encodes a subunit of 
the NuRD-chromatin-remodeling complex [14, 16]. A 
confirmatory study also noted frequent deletion of a small 
segment of chromosome 19 containing MBD3, another 
subunit of the NuRD-chromatin-modification complex, and 
frequent mutations in TAF1. The TAF1 protein has histone 
acetyltransferase activity and is an element of the TFIID 
basal transcription factor complex. Le Gallo et al., have 
reported TAF1 mutations in nearly 10% of clear cell EC 
[116]. Lower frequency mutations in several other chromatin 
remodeling genes including EP300 (8%), and ARID1A (6%) 
have been noted in serous ECs [14]. ARID1a, a component 
of the SWI/SNF chromatin remodeling complex, is also 
frequently mutated in endometrioid ECs including all 
TCGA subgroups except CNH, up to 40% by different 
databases [7, 117]. Overactivity/overexpression of EZH2, 
a histone methyl transferase, downregulates the suppressor 
ARID1a, creating a loss of suppressor function and resulting 
in increased proliferation, migration, and invasion of target 
malignant cells. Therapeutic inhibition of EZH2 is now in 
early evaluation and could be targeted to ARID1a mutant 
EC [118]. The expansion of the histone deacetylase inhibitor 
group and development of demethylating agents may be of 
use in this subset of patients.
THE PATH FORWARD FOR 
IDENTIFYING FUTURE ACTIONABLE 
OPPORTUNITIES
Clearly the emerging molecular data provide us with 
multiple potential avenues to pursue in terms of early phase 
clinical trial design for EC. In addition, TCGA identified 
molecular subgroups provide a potential framework for 
developing new risk stratification models. Actionable 
Figure 3: WNT Pathway: Most WNT signaling in EC occurs via the CTNNB1-dependent pathway. Possible targets 
include: use of WNT antagonists, reduced WNT ligand secretion, increased degradation of WNT and inhibition of CDK4/6 Canonical 
(left) and non-canonical (right) WNT signaling are shown. This file is licensed under the Creative Commons Attribution-Share Alike 3.0 
Unported license. https://en.wikipedia.org/wiki/Wnt_signaling_pathway.
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opportunities are those for which abnormalities have been 
identified and demonstrated to be biologically necessary 
and/or sufficient. We are now beyond the point of mutations 
being actionable by definition alone and require more than 
simple biologic plausibility. Refinement of the molecular 
subgroup model by combining conventional parameters, 
and potentially other biomarkers will add value and 
enhance potential for patient selection clinical trial designs. 
Incorporation of high quality, validated, correlative studies 
into our clinical trials with appropriate collection of tumor 
and surrogate samples will be essential to capitalize on the 
wealth of information that can be gained from positive and 
negative studies. Collaborative data sharing and access 
to samples for biomarker identification, and perhaps 
more importantly, validation will speed discovery. Lastly, 
translating opportunity and hypothesis into the clinic always 
requires consideration of other unique issues that may be 
found in patient populations. Endometrial cancer is now 
affecting younger women, though still remains a cancer 
predominantly of older women, many of whom have other 
medical comorbidities. Such clinical variables may affect 
the complexity of some of the combination treatment ideas 
that could be evaluated in EC. The clinical opportunities 
identified in this review illustrate the complexity of EC, 
and also provide us with a framework for leveraging 
combination strategies targeting the many interrelated 
pathways implicated in EC biology.
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